Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

 
• By Cathy Kelly
Biosimilar Uptake Needs A Reimbursement Boost, OIG Concludes • Source: Shutterstock

More from Market Access

More from Pink Sheet